The FDA could soon approve the first chimeric antigen receptor (CAR) T therapies for blood cancers, but this young field is still working on how to address solid tumours, safety concerns and manufacturing issues.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Holothurian triterpene glycoside cucumarioside A2-2 induces macrophages activation and polarization in cancer immunotherapy
Cancer Cell International Open Access 24 November 2023
-
Current progress in innovative engineered antibodies
Protein & Cell Open Access 18 August 2017
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kingwell, K. CAR T therapies drive into new terrain. Nat Rev Drug Discov 16, 301–304 (2017). https://doi.org/10.1038/nrd.2017.84
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.84
This article is cited by
-
Holothurian triterpene glycoside cucumarioside A2-2 induces macrophages activation and polarization in cancer immunotherapy
Cancer Cell International (2023)
-
Synapse-tuned CARs enhance immune cell anti-tumor activity
Nature Biotechnology (2023)
-
Human chimeric antigen receptor macrophages for cancer immunotherapy
Nature Biotechnology (2020)
-
Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy
Nature Biomedical Engineering (2018)
-
Current progress in innovative engineered antibodies
Protein & Cell (2018)
